article thumbnail

Arcturus Get Exit At Pliant

socalTECH

Pasadena-based venture capital firm Arcturus Capital has scored an exit out of its portfolio this morning, as Milpitas, California-based Pliant Technology was acquired by SanDisk in a deal worth $327M. SanDisk said it would pay $327M in cash, plus equity-based incentives for Pliant, a developer of enterprise solid state disk drives (SSDs).

Arcturus 150
article thumbnail

TrueCar Prices IPO

socalTECH

TrueCar is venture backed by backed by USAA, Capricorn Investment Group, Upfront Ventures, Anthem Ventures, Vulcan Capital Growth Equity, Peppy Capital Partners, Arcturus Venture Capital, along with others. TrueCar is trading on the NASDAQ Global Select Market as TRUE. READ MORE>>. truecar true buying service scott painter'

Truecar 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ondax Closes Round At $2.2M

socalTECH

The round was led by Prospector Equity Capital and Arcturus Capital, and also included the Pasadena Angels and Tech Coast Angels. Monrovia-based Ondax , a manufacturer of volume holographic grating filters and lasers, said Tuesday that it has officially closed its $2.2M, Series E funding round.

article thumbnail

Ondax Names New CEO

socalTECH

ONDAX is backed by Arcturus Capital, Prospector Equity Capital, and others. Moser is a native of Switzerland, and will remain as Chief Technology Officer at the firm. Heyler was most recently at Newport Corporation.

Arcturus 124
article thumbnail

Sorrento Therapeutics Gets $2.3M

socalTECH

in an equity funding round, according to a regulatory filing by the firm yesterday. Dr. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom. San Diego-based Sorrento Therapeutics , a new biotechnology startup, has raised $2.3M Source of the funding was not disclosed.

Arcturus 100
article thumbnail

Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More

Xconomy

The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.

Equity 84